Healthcare Industry News: diabetes
News Release - November 30, 2017
Fractyl Appoints Senator William W. Bradley and Dr. John Amatruda to the Company's Board of DirectorsLEXINGTON, Mass., Nov. 30, 2017 -- (Healthcare Sales & Marketing Network) -- Fractyl Laboratories Inc. (Fractyl) today announced the appointment of Senator William W. Bradley and Dr. John Amatruda to the company's board of directors. Fractyl is advancing the first medical device and procedure, called Revita™ DMR, to address type 2 diabetes and NAFLD/NASH. These insulin resistant metabolic diseases represent a major epidemic creating an enormous burden worldwide on patients and healthcare systems.
"At Fractyl, we are harnessing breakthrough scientific insights into the role of the gut in metabolism to advance a scalable procedural therapy that aims to reverse these diseases," said Harith Rajagopalan, M.D., Ph.D., cofounder and CEO of Fractyl. "To guide us as we advance this new medical device and procedure, we welcome to our board of directors: Senator Bradley, who has important experience in advising businesses on how to make a deep and enduring impact on the world, and Dr. Amatruda, who is an expert in metabolic disease research and drug development. Their experience and advice will be invaluable as Fractyl transforms the way type 2 diabetes and NAFLD/NASH are treated."
"Type 2 diabetes and other metabolic diseases caused by insulin resistance are an epidemic of staggering proportions, impacting hundreds of millions of people around the globe," said Senator Bradley. "I was impressed with the potential for Fractyl's innovative technology to fundamentally improve population health."
Dr. Amatruda concluded, "While we have a number of drugs for type 2 diabetes, we still find it difficult to control the disease for many patients. Fractyl breaks new ground in elucidating the importance of the duodenum in metabolic diseases and in developing an effective treatment procedure targeting insulin resistance. Fractyl's approach is a much needed alternative to escalating drug treatment."
Senator William (Bill) W. Bradley served in the U.S Senate from 1979 to 1997 representing the state of New Jersey. In 2000, he was a candidate for the Democratic nomination for President of the United States. Previously, he was chief outside advisor to McKinsey & Company's nonprofit practice and was a Senior Advisor and Vice Chairman of the International Council of JP Morgan & Co. He has worked as an essayist for CBS evening news and has authored seven books on American politics, culture and economy. Prior to serving in the Senate, he was an Olympic gold medalist in 1964 and a professional basketball player with the New York Knicks from 1967 to 1977. Senator Bradley holds a B.A. degree in American History from Princeton University and an M.A. degree from Oxford University where he was a Rhodes Scholar.
John Amatruda, M.D. is board certified in internal medicine, endocrinology and metabolism and has a proven track record in pharmaceutical discovery research and development. Dr. Amatruda has led drug discovery at Bayer and drug discovery and development at Merck for a number of programs, including metabolism, diabetes, obesity, atherosclerosis and cardiovascular disease, which resulted in five new drug applications. He holds several patents and has authored more than 100 publications in peer-reviewed journals. Dr. Amatruda received his B.A. from Yale University, his M.D. from the Medical College of Wisconsin, and completed his internship and residency in internal medicine and fellowship in endocrinology and metabolism at The Johns Hopkins Hospital.
About Fractyl and Revita™ DMR
Fractyl Laboratories is a private medical technology company aiming to improve the health of patients with metabolic diseases and relieve the burden these diseases cause for patients and healthcare systems. Based on breakthrough scientific insights, the company is developing a new medical device and procedure, called Revita DMR, to treat two highly prevalent metabolic diseases: type 2 diabetes and NAFLD/NASH. With a same-day, minimally invasive procedure, Revita DMR is designed to address insulin resistance at its source. The Revita DMR System received a CE mark in the European Union in April 2016. It has not been approved for investigational use by the U.S. Food and Drug Administration. The Revita DMR System may be available for investigational use in other regions. Fractyl is headquartered in Lexington, Mass.
For more information, visit www.fractyl.com or www.twitter.com/FractylLabs, or www.RevitaTrial.com.
Source: Fractyl Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.